| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Sorafenib | FAERS: 3 | US FAERS | |
| 2 | Daunorubicin | FAERS: 2 | US FAERS | |
| 3 | Lenalidomide | FAERS: 2 | US FAERS | |
| 4 | Aprepitant | FAERS: 1 | US FAERS | |
| 5 | Clofarabine | FAERS: 1 | US FAERS | |
| 6 | Pantoprazole | FAERS: 1 | US FAERS | |
| 7 | Pemetrexed | FAERS: 1 | US FAERS | |
| 8 | carbidopa, levodopa drug combination | FAERS: 1 | US FAERS | |
| 9 | clevidipine | FAERS: 1 | US FAERS | |
| 10 | Capecitabine | OFFSIDES | ||
| 11 | Cytarabine | OFFSIDES | ||
| 12 | Daunorubicin | OFFSIDES | ||
| 13 | Erlotinib Hydrochloride | OFFSIDES | ||
| 14 | Linezolid | SIDER | ||
| 15 | alfuzosin | OFFSIDES | ||
| 16 | ceftobiprole | SIDER |
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120240
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.